1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

  • January 2016
  • 28 pages
  • La Merie Publishing
Report ID: 3605803

Summary

Table of Contents

Search Inside

The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline of novel small molecule pan, selective or dual target bromodomain and extra-terminal domain (BET) family inhibitors suitable for treatment of cancer, inflammatory and cardiovascular diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. Bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease.


The report includes a compilation of currently active projects in research and development of novel small molecules targeting for treatment of hematologic malignancies, solid tumors, inflammatory and cardiovascular diseases. In addition, the report lists company-specific R&D pipelines of BET Inhibitors. Competitor projects are listed in a tabular format providing Information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product category/Therapeutic Area,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • Industry report
  • June 2017
  • by Datamonitor Healthcare

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin ...

OpportunityAnalyzer: Acute Myeloid Leukemia – Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • October 2017
  • by GlobalData

Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. Although a number of acquired genetic and ...

Pharmapoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • October 2017
  • by GlobalData

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, ...

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • September 2017
    2 pages
  • Cancer  

    Cancer  

  • United States  

View report >

Prostate Cancer Statistics in Sweden

  • September 2017
    8 pages
  • Prostate Cancer  

  • Sweden  

View report >

Hormone and Therapy Market in Pakistan and the US

  • September 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.